|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-4-12
|
|
pubmed:abstractText |
A feasibility study was performed to examine the safety and toxicity profile of daily gefitinib (250 mg) administration with concurrent definitive thoracic radiation therapy (TRT) in patients with unresectable non-small cell lung cancer (NSCLC) of stage III.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1872-8332
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
199-204
|
|
pubmed:meshHeading |
pubmed-meshheading:20828860-Aged,
pubmed-meshheading:20828860-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20828860-DNA Mutational Analysis,
pubmed-meshheading:20828860-Feasibility Studies,
pubmed-meshheading:20828860-Female,
pubmed-meshheading:20828860-Genes, erbB-1,
pubmed-meshheading:20828860-Humans,
pubmed-meshheading:20828860-Lung Neoplasms,
pubmed-meshheading:20828860-Male,
pubmed-meshheading:20828860-Middle Aged,
pubmed-meshheading:20828860-Mutation,
pubmed-meshheading:20828860-Neoplasm Staging,
pubmed-meshheading:20828860-Quinazolines,
pubmed-meshheading:20828860-Radiotherapy,
pubmed-meshheading:20828860-Withholding Treatment
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
|
|
pubmed:affiliation |
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan. chi-okamoto@dotd.med.kindai.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
